KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) Equity Average (2016 - 2025)

Historic Equity Average for Supernus Pharmaceuticals (SUPN) over the last 14 years, with Q3 2025 value amounting to $1.1 billion.

  • Supernus Pharmaceuticals' Equity Average rose 758.23% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 758.23%. This contributed to the annual value of $978.6 million for FY2024, which is 827.17% up from last year.
  • Per Supernus Pharmaceuticals' latest filing, its Equity Average stood at $1.1 billion for Q3 2025, which was up 758.23% from $1.0 billion recorded in Q2 2025.
  • Over the past 5 years, Supernus Pharmaceuticals' Equity Average peaked at $1.1 billion during Q3 2025, and registered a low of $749.7 million during Q1 2021.
  • Its 5-year average for Equity Average is $903.3 million, with a median of $916.0 million in 2023.
  • In the last 5 years, Supernus Pharmaceuticals' Equity Average skyrocketed by 2403.11% in 2021 and then soared by 290.98% in 2024.
  • Quarter analysis of 5 years shows Supernus Pharmaceuticals' Equity Average stood at $813.2 million in 2021, then grew by 6.93% to $869.5 million in 2022, then increased by 5.45% to $916.9 million in 2023, then grew by 11.41% to $1.0 billion in 2024, then increased by 3.46% to $1.1 billion in 2025.
  • Its Equity Average stands at $1.1 billion for Q3 2025, versus $1.0 billion for Q2 2025 and $1.0 billion for Q1 2025.